Form 8-K - Current report:
SEC Accession No. 0001437749-21-003299
Filing Date
2021-02-18
Accepted
2021-02-18 16:52:44
Documents
10
Period of Report
2021-02-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20210217_8k.htm 8-K 41498
2 EXHIBIT 1.1 ex_227272.htm EX-1.1 221867
3 EXHIBIT 4.1 ex_227273.htm EX-4.1 108499
4 EXHIBIT 5.1 ex_227274.htm EX-5.1 12147
5 EXHIBIT 99.1 ex_227275.htm EX-99.1 11940
6 EXHIBIT 99.2 ex_227276.htm EX-99.2 11734
7 EXHIBIT 99.3 ex_227277.htm EX-99.3 10476
8 EXHIBIT 99.4 ex_227561.htm EX-99.4 10734
9 dffn2.jpg GRAPHIC 8009
10 ex_227274img001.jpg GRAPHIC 2745
  Complete submission text file 0001437749-21-003299.txt   445408
Mailing Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902
Business Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

EIN.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 21650313
SIC: 2834 Pharmaceutical Preparations